Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled at WCLC 2024

Tomas Kauer - Moderator

Sep 9, 2024 - 01:00

Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled at WCLC 2024

Tags:

Previous Article

Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan W...

From Kennedy-Nixon to Harris-Trump: Six decades of debate quips, rips and slips

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Tomas Kauer - Moderator

Related Posts

Gold prices edge lower but keep record highs in sight ahead of inflation test

Gold prices edge lower but keep record highs in sight a...

Tomas Kauer - Mode... Sep 10, 2024

The LinkedIn games are fun, actually

The LinkedIn games are fun, actually

Tomas Kauer - Mode... Sep 15, 2024

U.S. government expands sanctions against spyware maker Intellexa

U.S. government expands sanctions against spyware maker...

Tomas Kauer - Mode... Sep 17, 2024